anti-GM2 monoclonal antibody (MabVax Therapeutics)

N/A

Report date: 2025/03/14 20:00:48

Base Information

Drug Nameanti-GM2 monoclonal antibody (MabVax Therapeutics)
Drug Alias NameHuMab-GM2
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionGanglioside GM2 modulators
TargetsUpdating
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesMabvax Therapeutics Holdings Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesMabvax Therapeutics Holdings Inc
Active IndicationsN/A
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A